Elana Kreiger-Benson

Elana Kreiger-Benson

Auto-generated profile, based on publicly available information

Elana Kreiger-Benson

NYU Grossman School of Medicine, New York, New York

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Journal of Clinical Neurology
Verified
Journal Article
Open access
PDF file
ALAriane Lewis
Ariane Lewis
JLJordan Liebman
Jordan Liebman
ABAzza Bakkar
Azza Bakkar
EKElana Kreiger-Benson
Elana Kreiger-Benson
AKAndrew Kumpfbeck
Andrew Kumpfbeck
DGDavid Greer
David Greer
Lewis A, et al. J Clin Neurol. 2020 Jul;16(3):480-490. https://doi.org/10.3988/jcn.2020.16.3.480

1 January 2021 in American Journal of Transplantation
Verified
Journal Article
Open access
EKElana Kreiger-Benson
Elana Kreiger-Benson
BGBruce Gelb
Bruce Gelb
HNHenry J. Neumann
Henry J. Neumann
SHSarah E. Hochman
Sarah E. Hochman
JLJennifer Lighter
Jennifer Lighter
SMSapna A. Mehta
Sapna A. Mehta
Solid organ transplant (SOT) candidates and recipients are at risk of significant morbidity and mortality from infection, including those circulating in the community from unexpected outbreaks. In late 2018-summer of 2019, a measles outbreak occurred in the New York City area, with a total of 649 cases reported. We developed a systematic 3-part approach to address measles risk in our adult SOT program through: (a) identification of nonimmune adults living in outbreak ZIP codes, (b) education focused on risk reduction for patients from outbreak ZIP codes, and (c) risk reduction for nonimmune patients. All waitlisted or previously transplanted patients residing in outbreak areas received a measles patient education handout. The electronic medical record of patients born in or after 1957 was reviewed for serologic evidence of measles immunity. Measles immunity testing was performed in patients without documentation of immunity. Patients who tested nonimmune were offered MMR vaccination or intravenous immunoglobulin depending on their transplant phase and risk profile. Thus, we demonstrate successful implementation of a systematic risk assessment during a large measles outbreak to identify and protect at-risk SOT patients. As vaccine hesitancy persists, our strategies may be increasingly relevant to transplant centers and those caring for immunocompromised patients.